Efficacy News and Research

RSS

GE Healthcare to showcase its sophisticated imaging systems for oncology at the ASTRO meeting

According to the American Cancer Society, more than one million people are diagnosed with cancer each year. In the United States, about 1 out of every 2 men and 1 out of every 3 women will have some type of cancer at some point during their lifetime. The sooner a cancer is detected and treatment begins, the better the patient’s chances for survival.

31 Oct 2009

Quintiles and Eisai partner to develop potential oncology products

Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.

31 Oct 2009

Study: Gene therapy can reduce symptoms of Huntington's disease

Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.

31 Oct 2009

ATLANTA-France study of the CATANIA Coronary Stent announced

Physicians at more than 40 centers in France have joined a study of the CATANIA(TM) Coronary Stent with NanoThin Polyzene®-F manufactured by CeloNova BioSciences. With Professor Emmanuel Teiger and Doctor Paul Barragan as co-Principal Investigators, the researchers today announced the Assessment of The Latest Non-Thrombogenic Angioplasty (ATLANTA-France) stent study. Each center will enroll 50 patients with the first procedures expected in early November.

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN).

30 Oct 2009

Cancer patients in northern Portugal to gain access to advanced cancer treatments

Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems (NYSE: VAR) by the Instituto Portugues Oncologia, IPO Porto.

30 Oct 2009

Repros Therapeutics signs settlement agreement with major creditors

Repros Therapeutics today announced that the Company has entered into a settlement agreement with its major creditors for the large majority of the debt incurred associated with the recently suspended Proellex® clinical program.

30 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

AcelRx Pharmaceuticals completes End-of-Phase 2 meeting with the FDA for its ARX-01drug/device

AcelRx Pharmaceuticals, Inc. today announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.

30 Oct 2009

IGR Genomic Center awarded ISO 9001 certification

The Institut de cancérologie Gustave Roussy (IGR) France announced today that its Genomic Center has been awarded ISO 9001 certification for quality management and compliance to the highest standards of quality by Association Française de Normalisation (AFNOR), France’s national organization for standardization and certification.

30 Oct 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the company that anticipates licensing its lead development programs and resuming development of earlier stage product candidates.

30 Oct 2009

New study reviews science behind the efficacy of biofield therapies on pain management

Biofield therapies, which claim to use subtle energy to stimulate the body's healing process, are promising complementary interventions for reducing the intensity of pain in a number of conditions, reducing anxiety for hospitalized patients and reducing agitated behaviors in dementia, over and above what standard treatments can achieve.

30 Oct 2009

Fiscal 2009 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the year ended July 31, 2009.

30 Oct 2009

MRG: Global spinal nonfusion technology market to increase up to $2 billion

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the global spinal nonfusion technology market will increase from approximately $400 million in 2008 to almost $2 billion by 2013.

30 Oct 2009

Online resource to illustrate genetic networks in common autoimmune diseases published

Currently, 5-8% of the U.S. population is afflicted with an autoimmune disease (www.niaid.nih.gov). Many of these are chronic and require life-long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways.

30 Oct 2009

VIVUS presents additional data on Qnexa Phase 3 trials

VIVUS, Inc. today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009.

30 Oct 2009

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Human Genome Sciences, Inc. today announced financial results for the quarter ended September 30, 2009, and provided highlights of recent key developments.

30 Oct 2009

GSK will ensure experimental malaria vaccine is affordable, CEO says

GlaxoSmithKline CEO Andrew Witty said Wednesday the company would ensure that if an experimental malaria vaccine works, it would be priced reasonably, Reuters reports. "The vaccine, called Mosquirix [or RTS,S] and the first malaria shot to make it to final-stage trials, is creating a buzz ahead of a conference of 1,500 malaria experts in Nairobi next week," writes Reuters.

29 Oct 2009

Efficacy News and Research

GE Healthcare to showcase its sophisticated imaging systems for oncology at the ASTRO meeting

Quintiles and Eisai partner to develop potential oncology products

Study: Gene therapy can reduce symptoms of Huntington's disease

ATLANTA-France study of the CATANIA Coronary Stent announced

Data from multiple clinical and preclinical studies evaluating Hematide announced

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Cancer patients in northern Portugal to gain access to advanced cancer treatments

Repros Therapeutics signs settlement agreement with major creditors

Eisai reports global Phase III study results of eribulin mesylate

AcelRx Pharmaceuticals completes End-of-Phase 2 meeting with the FDA for its ARX-01drug/device

IGR Genomic Center awarded ISO 9001 certification

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

New study reviews science behind the efficacy of biofield therapies on pain management

Fiscal 2009 results announced by Helix BioPharma

MRG: Global spinal nonfusion technology market to increase up to $2 billion

Online resource to illustrate genetic networks in common autoimmune diseases published

VIVUS presents additional data on Qnexa Phase 3 trials

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

GSK will ensure experimental malaria vaccine is affordable, CEO says

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News